EGFR inhibitors
BostonGene, Saga University Partner to Study Lung Cancer Immunotherapy Biomarkers
Investigators will conduct a study analyzing features of the tumor microenvironment in EGFR-positive patients, exploring response and resistance mechanisms.
FoundationOne Liquid Biopsy Assay Gets FDA OK as Companion Diagnostic for Takeda's Exkivity
Foundation Medicine said its assay is the only blood-based comprehensive genomic profiling platform to have gained this approval for Takeda's EGFR drug.
FDA Approves Foundation Medicine Assay as CDx for Certain NSCLC Therapies
The FoundationOne Liquid CDx test can be used with Tarceva (erlotinib), Tagrisso (osimertinib), and Iressa (gefitinib), and other TKIs approved in the future.
Repeat Biomarker Testing Informs Next Steps for Treatment-Resistant EGFR-Mutant NSCLC Patients
Premium
Studies at ESMO showed the importance of repeat biomarker testing to guide treatment after resistance to AstraZeneca's Tagrisso, but tissue-based testing remains a hindrance.
FDA Approves FoundationOne CDx for EGFR Inhibitors to Identify EGFR Mutations in NSCLC
The FoundationOne CDx test will be used to identify patients for treatment with FDA-approved EGFR inhibitors.